臨牀消化器内科 Vol.23 No.13(2-1)


特集名 急性肝不全と再生医療
題名 劇症肝炎の治療 (1) B型肝炎ウイルス関連劇症肝炎の治療
発刊年月 2008年 12月
著者 渡邊 綱正 昭和大学藤が丘病院消化器内科
著者 井上 和明 昭和大学藤が丘病院消化器内科
著者 与芝 真彰 昭和大学藤が丘病院消化器内科
【 要旨 】 「劇症肝炎」とは,先行する肝疾患がなく,広範な肝細胞障害に基づく出血傾向と意識障害を特徴とする症候群である.B型肝炎ウイルス(HBV)関連劇症肝炎においては,わが国では,原因がHBVの急性感染による場合と,キャリア発症の場合が存在し,両者は病態,予後,治療上の対応も異なっている.前者は原因ウイルスが急速に排除されるため,肝不全期間を肝補助でサポートすれば一般に予後は良好である.後者は持続感染状態のキャリアにウイルス増殖が先行し,その後強い宿主の免疫応答により肝細胞破壊が起こり発症するものである.ウイルス増殖が持続するため原疾患治療が必要であることと,さらに先行肝病変が予後に大きく影響することから,可及的早期に劇症化を予知し,肝炎を終息させることが治療上重要である.
Theme Acute Liver Failure and Regenerative Medicine of the Liver
Title Management of Fulminant Hepatitis Related to Hepatitis B Virus Infection
Author Tsunamasa Watanabe Division of Gastroenterology, Showa University Fujigaoka Hospital
Author Kazuaki Inoue Division of Gastroenterology, Showa University Fujigaoka Hospital
Author Shinsho Yoshiba Division of Gastroenterology, Showa University Fujigaoka Hospital
[ Summary ] Fulminant hepatitis (FH) is defined as severe hepatitis caused by rapid and extensive hepatocyte destruction in patients without a previous history of liver disease. However, in relation to FH caused by the hepatitis B virus (HBV), the term FH causes difficalties, because of fulminant hepatic failure (FHF) occurring during chronic HBV infection. In Japan, there are two kinds of FHF, including FH, related to HBV. One is FH-B, caused by acute infection with HBV and the other is FHF-B, occurring during chronic HBV infection. The difference between the two types of infection is their pathogenesis and prognosis. The prognosis for FH-B, due to acute infection, is generally favorable when patients are kept alive through intensive liver support such as the one we originated. This is true except for the "hyperacute type", in which the whole liver is almost instantaneously destroyed at the onset of the disease, and accordingly considered to be the "hyper acute type". That type of patient is an absolutely indicated for liver transplantation. The prognosis for FHF-B accompanied by chronic infection is generally less favorable, unless both persistent HBV replication and enhanced host immune reactions are effectively suppressed by the combination of antiviral and immunosuppressive treatments. If the start of treatment is delayed, patients must receive liver transplants which is very difficult for these patients.
戻る